Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.

Bibliográfalaš dieđut
Váldodahkkit:	Isaacs, J, Hale, G, Waldmann, H, Dick, A, Haynes, R, Forrester, J, Watson, P, Meyer, P
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	1995

Geahča maid

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.
Dahkki: Newman, D, et al.
Almmustuhtton: (1995)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
Dahkki: Isaacs, J, et al.
Almmustuhtton: (1996)

Campath-1H therapy in refractory ocular inflammatory disease.
Dahkki: Dick, A, et al.
Almmustuhtton: (2000)

Specificity of monoclonal antibody Campath-1.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1994)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
Dahkki: Watts, R, et al.
Almmustuhtton: (1992)

EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY
Dahkki: Dyer, M, et al.
Almmustuhtton: (1988)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (1985)

CAMPATH-1H in inflammatory arthritis.
Dahkki: Watts, R, et al.
Almmustuhtton: (1993)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
Dahkki: Friend, P, et al.
Almmustuhtton: (1991)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
Dahkki: Waldmann, H, et al.
Almmustuhtton: (1985)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
Dahkki: Lim, S, et al.
Almmustuhtton: (1993)

Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
Dahkki: Naparstek, E, et al.
Almmustuhtton: (1999)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
Dahkki: Dyer, M, et al.
Almmustuhtton: (1990)

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
Dahkki: Rebello, P, et al.
Almmustuhtton: (1999)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Dahkki: Williams, R, et al.
Almmustuhtton: (2000)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1986)

Availability of Campath-1 antibodies for bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1995)

A personal history of the CAMPATH-1H antibody.
Dahkki: Waldmann, H
Almmustuhtton: (2002)

Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1985)

CAMPATH: from concept to clinic.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (2005)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
Dahkki: Hale, G, et al.
Almmustuhtton: (1996)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
Dahkki: Dyer, M, et al.
Almmustuhtton: (1989)

CAMPATH-1 antibodies in stem-cell transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (2001)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
Dahkki: Dyer, M, et al.
Almmustuhtton: (1989)

Delayed allograft rejection in primates treated with anti-IL-2 receptor monoclonal antibody Campath-6.
Dahkki: Tighe, H, et al.
Almmustuhtton: (1988)

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Dahkki: Lundin, J, et al.
Almmustuhtton: (2002)

ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA USING CAMPATH-1 MONOCLONAL-ANTIBODIES AND POSTTRANSPLANT ALLOIMMUNIZATION WITH DONOR LYMPHOCYTES
Dahkki: Naparstek, E, et al.
Almmustuhtton: (1993)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
Dahkki: Killick, S, et al.
Almmustuhtton: (1997)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Dahkki: Hale, G, et al.
Almmustuhtton: (2002)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
Dahkki: Watson, C, et al.
Almmustuhtton: (2004)

Successful haploidentical mismatched bone marrow transplantation in severe combined immunodeficiency: T cell removal using CAMPATH-I monoclonal antibody and E-rosetting.
Dahkki: Morgan, G, et al.
Almmustuhtton: (1986)

In vivo 'purging' of residual disease in CLL with Campath-1H.
Dahkki: Dyer, M, et al.
Almmustuhtton: (1997)

Direct antibody rosette-forming reactions using monoclonal markers of lymphocyte subpopulations. Methodology and applications illustrated by investigations with rat pan-T antibodies of the CAMPATH series.
Dahkki: Wilson, AB, et al.
Almmustuhtton: (1986)

1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
Dahkki: James, L, et al.
Almmustuhtton: (1999)

Inflammation, demyelination, and axonal degeneration: Three aspects of the pathogenesis of multiple sclerosis revealed by campath-1H treatment
Dahkki: Coles, A, et al.
Almmustuhtton: (2003)

HUMANIZED MONOCLONAL-ANTIBODY THERAPY IN RHEUMATOID-ARTHRITIS
Dahkki: Isaacs, J, et al.
Almmustuhtton: (1992)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
Dahkki: Clatworthy, MR, et al.
Almmustuhtton: (2009)

Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis.
Dahkki: Greenwood, J, et al.
Almmustuhtton: (1994)